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Abstract: The number of non-melanoma skin cancers is increasing worldwide, and so also 
the demand for effective treatment modalities. Topical photodynamic therapy (PDT) using 
aminolaevulinic acid or its methyl ester has recently become good treatment options for actinic 
keratosis and basal cell carcinoma; especielly when treating large areas and areas with ﬁ  eld 
cancerization. The cure rates are usually good, and the cosmetic outcomes excellent. The only 
major side effect reported is the pain experienced by the patients during treatment. This review 
covers the fundamental aspects of topical PDT and its application for treatment of actinic 
keratosis and basal cell carcinoma. Both potentials and limitations will be reviewed, as well as 
some recent development within the ﬁ  eld.
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Introduction
The number of skin cancers has increased annually for many years (Marks 1995). 
One of the most important etiologic factors is considered to be sun exposure. Staying 
out in the sun during a prolonged time and repeated sun burns are clear risk factors 
for the development of different types of skin cancer. This is especially applicable on 
persons having lighter complexion (skin type I-II).
There are mainly three forms of malignant tumors of the skin. These are malignant 
melanoma, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). BCC 
and SCC belong to the group of non-melanoma skin cancer (NMSC), which is the 
most common skin malignancy worldwide (Miller 1991; Green 1992). Actinic kera-
tosis (AK) and squamous cell carcinoma in situ (SCCIS), also called Morbus Bowen, 
are precursors of SCC and therefore also normally are ascribed the NMSCs. The 
incidence of NMSC is increasing steadily (Green 1992), and the association between 
skin type, solar habits and NMSC is well known. Furthermore, once a patient has had 
a NMSC, additional lesions are common (Frankel et al 1992). Also, organ transplant 
recipients (OTR) run an extremely high risk of contracting NMSC (Adami et al 2003; 
Bouwes Bavinck et al 2007). Consequently, an increasing number of patients seek 
care with sun damaged skin and skin tumors and the patients must be taken care of 
in an effective manner.
During recent years, several therapeutic modalities have been available for 
superﬁ  cial skin cancer. One of those is photodynamic therapy (PDT), which involves 
the activation of a photosensitizer using visible light (Henderson and Dougherty 1992). 
This results in the formation of reactive and cytotoxic singlet oxygen. PDT is a relatively 
new therapeutic method and it has become a good complement in this respect to already 
established treatments of skin cancer of non-melanoma type, particularly because of 
the good cosmetic outcome which is increasingly important, as recently reviewed by 
other authors (Morton 2004; Marmur et al 2004; Kormeili et al 2004; Lehmann 2007; 
Braathen et al 2007). The current review will address PDT of BCC and AK, which Therapeutics and Clinical Risk Management 2008:4(1) 2
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are the most common applications of topical-PDT within 
dermatology today. Also the fundamental aspects and recent 
developments of the treatment will be covered.
Actinic keratosis (AK)
SCC and AK represent the same disease process at different 
stages of evolution (Cockerell 2000), ie, AKs are prolifera-
tions of transformed, neoplastic keratinocytes conﬁ  ned to 
the epidermis, whereas SCC extend more deeply including 
dermis. Thus AK lesions are considered as pre-cancerous or 
pre-malignant, and a few of the lesions progress to SCCIS 
or SCC. AKs are extremely prevalent and strongly related to 
sun exposure. The lesions occur on the dorsum of the hands, 
the face, scalp and other sun exposed sites. AKs are often 
multiple and recently the concept of ‘ﬁ  eld cancerization’ has 
been discussed, meaning that the clinically normal appearing 
skin around AKs provides the basis for clonal expansion of 
genetically altered neoplastic cells (Braakhuis et al 2003). 
This means that an entire area has undergone solar damage 
with precancerous and cancerous lesions. Field cancerization 
can, for example, occur in the face. It is clinically difﬁ  cult to 
distinguish between a proliferative AK and an early invasive 
SCC. As ﬁ  eld cancerization often occurs, it is necessary with 
a treatment that not only involves overt AK, but also treats 
subclinical lesions nearby. For this reason, topical PDT 
which is a non-invasive method, has become an important 
treatment modality.
Basal cell carcinoma
Of the NMSCs, BCCs are the most common (Miller 1991). 
Of all BCCs, 85% appear in the head and neck region. BCCs 
almost never metastasize but can destroy the tissue locally 
and thus have to be treated. Particularly this has to be kept in 
mind when located in the H-zone. The BCCs can be divided 
into three variants according to histopathological pattern 
and degree of aggressiveness (Miller 1991; Champion et al 
1998). The most common is nodular BCC, which grows 
in large, normally well delineated, rounded, nests pushing 
into dermis. Nodular BCC accounts for approximately 60% 
of the BCCs, and is most frequently observed in the face. 
Superﬁ  cial BCC has a growth pattern where the tumor nests 
are restricted to epidermis or superﬁ  cial parts of hair follicles. 
The most common location of the superﬁ  cial BCCs is on 
the trunk. The third and most aggressive type is morpheic 
BCC, which has an inﬁ  ltrative growth pattern. The tumor 
nests are diffuse and irregularly spread, and are often found 
in subcutis. This type of BCC is often located on the central 
face, ie, on the nose, lips, ears and around the eyes, with 
a higher risk of recurrence after treatment compared to other 
locations. Transitions between the different types of BCC 
may occur. Regarding therapy, the H-zone location is very 
important to keep in mind concerning the high recurrence 
risk, while, usually, superﬁ  cial BCC outside this area run 
a low risk. Topical PDT is today an accepted treatment for 
superﬁ  cial BCC.
Non-melanoma skin cancer in organ 
transplant recipients(OTRs)
OTRs have been reported to run a more than ﬁ  fty times 
increased risk of contracting SCC because of their immu-
nosuppressive therapy (Adami et al 2003). Many of these 
patients obtain widespread AK. Heart transplant patients 
are particularly susceptible because of their older mean age 
and the requirement for more aggressive immunosuppressive 
therapy. Therefore, efﬁ  cient treatment modalities are required 
to be able to treat these patients, and topical-PDT has recently 
become an interesting treatment option.
Basic aspects of PDT
The fundamental approach of PDT is initial photosensiti-
zation of the treatment site, followed by irradiation with 
visible light, which initiates a tissue-toxic photochemical 
reaction (Henderson and Dougherty 1992). The ﬁ  rst attempts 
at PDT were reported by Tappeiner and Jesionek as early 
as in 1903 (Tappeiner and Jesionek 1903). But it was not 
until in 1972, Diamond and co-workers found that tumor 
cells were destroyed by visible light after sensitization 
using hematoporphyrin derivative (Diamond et al 1972). 
Thereafter Dougherty et al (1978) initiated clinical studies 
of PDT of various malignant tumors with promising results. 
Today, most commonly, the photosensitization for PDT of 
superﬁ  cial skin lesions is obtained by topical application of 
δ-5-aminolaevulinic acid (ALA) or its methyl ester (MAL) 
(Peng et al 1997; Salva 2002; Braathen et al 2007). The 
main advantages of topical PDT are that the method is non-
invasive and effective, and generally gives a good cosmetic 
outcome. The application of ALA or MAL enhances the 
formation of protoporphyrin IX (PpIX) in the skin. The 
tumor is irradiated with light matching the absorption of 
PpIX, which initiates the photochemical reaction, in which 
reactive singlet oxygen is formed. The singlet oxygen is 
generally believed to be one of the key factors for the desired 
therapeutic effect of PDT (Weishaupt et al 1976; Moan and 
Sommer 1985). Consequently, the presence of appropriate 
concentration of sensitizer, light matching the absorption of Therapeutics and Clinical Risk Management 2008:4(1) 3
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the sensitizer and molecular oxygen in the tissue, is crucial 
for the efﬁ  ciency of PDT.
Photosensitizing drugs for topical PDT
The early photosensitisers for PDT were based on hematopor-
phyrin derivatives, which were directly injected into the tumors 
(Peng et al 1997). The main drawback however was prolonged 
and systemic photosensitivity, persisting around 4–6 weeks. 
Kennedy et al investigated the possibility to use endogenously 
formed PpIX obtained after application of ALA, a precursor 
in the haem synthesis (Kennedy et al 1990; Kennedy and 
Pottier 1992). The results were promising, and the drawbacks 
of systemic and prolonged photosensitization were eliminated. 
Instead, a local photosensitization of the application site was 
found up to 48 hours. Since then, topical ALA-PDT has been 
widely investigated for treatment of superﬁ  cial skin lesions, 
eg, BCCs and AK. In addition to ALA, a number of ALA 
esters have been investigated (Lopez et al 2004). The methyl-
ester, ie, 16% MAL, has gained drug approval and is the sole 
commercially available drug for topical PDT in Europe with 
the trade name Metvix® (Galderma & Photocure ASA). While 
in the USA, 20% ALA in ethanol solution is the approved drug, 
ie, Levulan® (DUSA Pharmaceuticals, Inc.).
It has been known for a long time that certain abnor-
malities in the haem synthesis, ie, porphyria, lead to 
extensive photosensitization because of the accumulation 
of porphyrins particularly PpIX (Bottomley and Muller-
Eberhard 1988). But the group of Pottier et al (1986) was 
the ﬁ  rst to demonstrate the accumulation of PpIX after 
injection of exogenous ALA in mice. The formation of 
haem takes place in the mitochondrial and the cytosolic 
compartments of the cells. The primary substrates in the 
production of haem are glycine and succinyl CoA, from 
which ALA is formed. This is the rate-limiting step in the 
pathway, due to negative feedback control by haem. By 
applying exogenous ALA this step is bypassed leading to 
an accumulation of PpIX in the tissue. Two enzymes have 
been reported to be of particular importance for the accu-
mulation of PpIX in tissue after topical application of ALA. 
These enzymes are porphobilinogen deaminase (PBGD) 
and ferrochelatase (FC). Increased activity of PBGD, 
in connection with decreased FC activity in neoplastic 
tissue, have been reported to be possible factors behind 
the selective accumulation of PpIX (Dailey and Smith 
1984; Leibovici et al 1988; Kondo et al 1993; Hinnen 
et al 1998; Gibson et al 1998). The metabolic pathway of 
MAL is generally believed to be the same as ALA, but 
the transportmechanism into the cells have been shown 
to differ (Rud et al 2000; Gederaas et al 2001; Rodriguez 
et al 2006). In addition, the the methyl-ester must be dehy-
drolyzed at some stage, but it is not clear in which step the 
ester hydrolysis is undertaken.
Selective accumulation between tumor and normal tissue 
has been observed using ALA-induced PpIX sensitization 
(El-Far et al 1990; Kennedy and Pottier 1994; Abels et al 
1994; Andersson-Engels et al 1995). When ALA is applied 
systemically, the selectivity is most likely explained by 
altered enzymatic activity in the tumor cells, as described 
above. Although, the stratum corneum, ie, the outer skin 
barrier, seems to be the factor of major importance for the 
selectivity, since it has a large impact on the penetration 
of ALA through the skin (Moan et al 2001). The abnormal 
keratin layer that is produced by BCCs or SCCs is rapidly 
penetrated by ALA, while the adjacent normal skin with 
intact stratum corneum is less permeable. This has been 
veriﬁ  ed in vivo, where the ALA penetration was found to 
be higher in BCC compared to the surrounding normal skin 
by microdialysis studies (Wennberg et al 2000). Conse-
quently, higher concentrations of ALA will result in higher 
amounts of PpIX in the tumor. The ﬂ  uorescence contrast after 
application of ALA has been found to be time dependent with 
an optimum around 3 hours in BCCs (Ericson et al 2003). 
There are indications that MAL is more selective towards 
neoplastic tissue compared to ALA (Angell-Petersen et al 
2006), although there is a lack of comparing studies verifying 
this relationship.
When ALA or MAL is applied topically, sufficient 
amounts of drug have been found to be present in both epi-
dermis and dermis, although the dermal cells do not develop 
signiﬁ  cant PpIX levels to become photosensitized (Divaris 
et al 1990). Hence, only epidermis becomes sensitized. 
This makes it possible to treat epidermal cancers without 
damaging dermis, which might be the reason why scarring 
is uncommon in topical ALA-PDT. It has been shown that 
the cellular localization of PpIX after ALA application is 
restricted to the mitochondria (Peng et al 1992; Iinuma et al 
1994; Malik et al 1996). Hence, the initial photodynamic 
damage will be localized to this organelle. The subsequent 
apoptosis of the cells has been reported to occur within 10 
hours (Webber et al 1996).
In order to improve topical drug delivery of ALA or 
MAL, some attempts have been made. Soler et al (2000) 
used a formulation including DMSO for delivery of 20% 
ALA. Other recent publications report on the use of cubic-
lipid-systems (Bender et al 2005), and a bioadhesive 
patch (McCarron et al 2006). However, so far there is a Therapeutics and Clinical Risk Management 2008:4(1) 4
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lack of studies verifying the clinical response using these 
methods.
Light sources and dosimetry
Whatever the choice of light source for PDT, two criteria 
have to be fulﬁ  lled. Firstly, the wavelength must match the 
absorption of the sensitizer in order to induce the desired 
photochemical reaction. The second criterion is that the 
light must be able to penetrate the tissue, so that the depth 
of the tumor can be treated. Due to the presence of melanin, 
hemoglobin, oxyhemoglobin and water, the absorption of 
visible light is high in biological tissue (Tuchin 2000). But 
the absorption has a minimum in the wavelength region 
600–1000 nm, ie, the “optical window” of tissue (Richards-
Kortum and Sevick-Muraca 1996). In this region, the light 
propagation is dominated by scattering, and the penetration 
depth is around 8–10 mm. Therefore, normally red light 
centered around 635 nm is used to ensure therapeutic ﬂ  u-
ence rates for topical PDT (Peng et al 1997; Salva 2002; 
Braathen et al 2007), even though the maximum absorption 
of PpIX is around 400 nm. But successful treatment of AK 
with ALA-PDT and blue light has been reported (Jeffes et al 
2001; Zelickson et al 2005).
Both coherent and incoherent light sources have been 
applied for PDT of various diseases. Lasers offer signiﬁ  cant 
advantages whenever ﬁ  bre optics are needed. In addition 
lasers have the advantage of producing monochromatic 
light, exactly matching the absorption band of the sensitizer. 
In this way excessive heating is avoided. Various lasers 
have been applied in PDT, eg, Svanberg et al (1994), but 
the major drawbacks are their bulkiness and the fact that 
they are expensive. Moreover, the area of irradiation is 
limited, so the beam has to be scanned in order to treat 
larger areas.
Filtered broadband lamps have proven to be very useful 
for the treatment of superﬁ  cial lesions (Wennberg et al 1996; 
Varma et al 2001). The main advantages are that they are 
relatively inexpensive, but the wavelength bands are usually 
quite broad, 50–130 nm, and they can be quite bulky. The 
wavelengths outside the absorption spectrum of the photosen-
sitiser were earlier thought to have no therapeutic effect, other 
than hyperthermia. On the other hand, it has been discussed 
that the excitation of photoproducts absorbing around 670 
nm might actually contribute to the photodynamic reaction 
(Peng et al 1997); but the results are contradictory (Soler et al 
2000; Clark et al 2003). Recently, so-called intense pulsed 
light (IPL) has been evaluated for PDT (Kim et al 2005; 
Gold et al 2006), although there is a report on dramatically 
decreased PDT reaction using IPL compared to broad-band 
light source (Strasswimmer and Grande 2006).
Light-emitting diodes (LED) can also be used as light 
sources for PDT (Thompson et al 2001; Yang et al 2003). The 
wavelength band is narrower compared with ﬁ  ltered lamps. 
The earlier problem with LEDs has been their relatively low 
intensity, although the recent generation of LEDs seems to 
provide sufﬁ  cient intensities for PDT of superﬁ  cial skin 
lesions. These light sources are very compact and cheap, 
which is of great preference for clinical practice.
Light dosimetry and oxygen depletion
Despite the fact that PDT is a rather well accepted treatment 
modality for treatment of NMSC, there exists no common 
light dosimetry guide. Because of the wide variety of light 
sources, the reported light doses and ﬂ  uence rates used for 
PDT have a broad span, ranging from 50 to 500 J/cm2 and 50 
to 200 mW/cm2 respectively (Dougherty et al 1998; Rada-
kovic-Fijan et al 2005). Fluence rates below 150 mW/cm2 
should be used to avoid hyperthermia (Peng et al 1997). In 
addition, oxygen depletion is of concern at ﬂ  uence rates 
above 50 mW/cm2 for PDT of AK (Ericson et al 2004). This 
is veriﬁ  ed by experimental studies in rodents (Sitnik et al 
1998; Robinson et al 1999; Iinuma et al 1999; Bissonnette 
et al 2004), cell spheroids (Foster et al 1993), and mathemati-
cal modeling (Foster et al 1991), showing signiﬁ  cantly better 
results when low ﬂ  uence rates are applied. These results are 
most likely related to oxygen depletion at high ﬂ  uence rates 
(Tromberg et al 1990).
Since the presence of singlet oxygen is crucial for the 
photodynamic reaction, it would be desirable to be able to 
monitor its formation in vivo. Unfortunately, there exists 
no simple method of direct detection of singlet oxygen in 
biological tissue (Gorman and Rodgers 1992), but there have 
been attempts with some success in keratinocytes (Bilski et al 
1998). Different oxygen sensors have been investigated in 
pre-clinical studies for monitoring the oxygen tension during 
PDT (Curnow et al 2000), although this has so far not been 
investigated in patients. Another possibility is in vivo moni-
toring of the photobleaching of the sensitizer. In the clinical 
study presented by Ericson et al (2004) it was reported that 
the treatment outcome indeed was found to be ﬂ  uence-rate-
dependent and correlated to the rate of photobleaching, where 
low ﬂ  uence rates were found preferable.
Light fractionation
It has been suggested that light fractionation should be 
performed to minimize the effect of hypoxia during PDT. Therapeutics and Clinical Risk Management 2008:4(1) 5
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Splitting up the light dose in minor fractions would allow 
oxygen to diffuse back into the cells, increasing the efﬁ  ciency 
of the treatment. Theoretical calculations have predicted that 
effective reoxygenation takes place already after 45 s (Foster 
et al 1991). In vivo studies in rodents state that dark interval 
of 150 s is required (Curnow et al 2000). Other reports with 
2 hours’ dark period show similar results (Robinson et al 
2000; Robinson et al 2003). For this reason, various illumi-
nation schemes have been suggested. For example, de Haas 
et al (2006) suggest that 20 + 80 J/cm2 given at a ﬂ  uence rate 
of 50 mW/cm2 is more effective than a single treatment of 
75 J/cm2 when treating superﬁ  cial BCCs. Earlier reports based 
on results from an animal model recommend 5 + 95 J/cm2 
(Robinson et al 2000; Robinson et al 2003). Other investiga-
tors have failed to show an effect when using fractionated 
PDT (Babilas et al 2003), which implies that the choice of 
illumination scheme is important in order to obtain an effect 
of the fractionation minimizing hypoxia during PDT.
Clinical studies with PDT of AK
AK typically appears as ﬁ  eld cancerization of large areas 
in the head and face region. Thus PDT has proven to be an 
excellent treatment modality for this subgroup of patients, 
because of the ability to treat large areas and preferable 
cosmetic outcome. Both ALA and MAL have been applied 
as photosensitizisers for PDT of AK. No comparable study 
currently exists, although the cure rates seem to be similar 
by reviewing the literature.
The long-term cure rate for PDT using 20% ALA solution 
(14–18 hours application), blue light (10 mW/cm2, 10 J/ cm2), 
and two treatments was reported to be 78% after 12 months 
follow up (Tschen et al 2006). Another study reports on 
89% cure rate at 3 month follow up using a similar treatment 
protocol (Piacquadio et al 2004). In a light-dose ranging 
study complete response using 20% ALA cream (3 hours 
application), red light (30 mW/cm2, 100 J/cm2), and single 
treatment was found to be 89% at two months follow up in 
the low ﬂ  uence rate group (Ericson et al 2004). Similar treat-
ment protocol, but two treatments and red light (70 mW/cm2, 
70 J/cm2), resulted in 85% complete response (Sandberg et al 
2006). A study has been performed comparing 5-ﬂ  uorouracil 
(5-FU) to a single treatment of ALA-PDT, with comparable 
results (Kurwa et al 1999).
Cure rates for PDT with 16% MAL (3 hours’ application), 
red light (75 J/cm2), and two treatments were reported to be 
89%–91% at 3-month follow-up (Pariser et al 2003; Freeman 
et al 2003). When treating thin actinic keratosis, it seems 
that one treatment is sufﬁ  cient using MAL-PDT, although 
two treatments are recommended for more hyperkeratotic 
lesions (Tarstedt et al 2005). Studies comparing the outcome 
by two consecutive topical MAL-PDTs versus cryotherapy 
have been performed for AKs (Szeimies et al 2002; Morton 
et al 2006). The cure rates were found similar although the 
cosmetic results were superior using PDT. In addition, the 
patients were found to prefer PDT over cryotherapy.
Clinical studies with PDT of BCC
Superﬁ  cial BCC
Several studies have been performed investigating PDT for 
superﬁ  cial BCCs. For example, Wennberg et al (1996) report 
a 91% clearance of superﬁ  cial BCCs treated with single 
sessions of 20% ALA-gel (4 hours’ application) and red 
light (125–166 mW/cm2, 75–100 J/cm2). Soler et al (2000) 
found no differences in cure rates, ie, 82%–86%, compar-
ing laser (630 nm, 120–150 mW/cm2, 100–150 J/cm2) and a 
broad band light source (100–180 mW/cm2, 150–200 J/cm2) 
when treating superﬁ  cial BCCs with ALA-PDT. Horn et al 
(2003) demonstrated clearance rates at 92% when using two 
consecutive treatments of MAL-PDT (16% MAL, red light). 
The cosmetic results are usually excellent and relatively large 
areas can be treated.
Nodular basal carcinoma
There is some evidence for using topical PDT in nBCCs 
(Horn et al 2003; Vinciullo et al 2005). However, a careful 
curettage was carried out before application of the MAL-
cream. Rhodes et al (2004) demonstrated potential problems 
with long-term recurrence rates when treating nodular BCC 
with MAL-PDT. In order to improve cure rates for PDT of 
nodular BCCs, intralesional treatment protocol has been sug-
gested (Cappugi et al 2004). Again, the cosmetic outcomes 
with PDT are generally impressive. Thus, topical-PDT can be 
a preferable treatment choice for nodular BCCs in ‘difﬁ  cult-
to-treat’ areas, although special pre-operative handling is 
necessary.
Morpheic basal cell carcinomas
Morpheic BCCs shall not be treated with PDT. Instead, 
a Mohs’ micrographic surgery is the golden standard 
(Wennberg et al 1999).
PDT in organ transplanted 
recipients
Recently, topical PDT has become an interesting treatment 
modality for dealing with NMSC among OTRs, who exhibit 
an increased risk of contracting NMSC due to their immune Therapeutics and Clinical Risk Management 2008:4(1) 6
Ericson et al
suppression. Both ALA-PDT and MAL-PDT seem to be able 
to deal with AK and other epidermal dysplasia among OTRs 
(Dragieva et al 2004; Wulf et al 2006; Wennberg et al 2005). 
It appears that the therapeutic results from PDT are superior 
to that from 5-FU (Perrett et al 2007). Topical PDT in OTRs 
has been suggested to have a prevention potential prohibiting 
the development of new lesions (Wulf et al 2006), although 
contradicting results exist (de Graaf et al 2006).
Side effects of PDT
Acute
PDT is generally well tolerated. Immediately after treat-
ment an erythema and a slight oedema is often seen. Crusts 
and superﬁ  cial erosions are typically seen after a few days. 
Severe ulceration is rare. The most bothersome acute side 
effect is pain (Kennedy and Pottier 1992; Fijan et al 1995). 
Most patients experience a burning sensation, also described 
as ‘stinging’ or ‘prickling’, in the ALA-treated area during 
light exposure. The mechanism for this reaction is not clear. 
A possible explanation is hyperthermia of the tissue; how-
ever, Orenstein et al (1995) obtained performed IR imaging 
and could not relate the pain sensation with a temperature 
increase. This implies that the pain sensation is a consequence 
of the photochemical reaction in the tissue, and related to the 
presence of reactive singlet oxygen. This is consistent with 
the clinical experience that the peak pain is obtained after a 
few minutes of irradiation when the photodynamic activity is 
high, and then gradually decreased towards the background 
level (Kennedy and Pottier 1992; Ericson et al 2004).
It has been reported that the site of the lesion is of impor-
tance for the pain sensation (Grapengiesser et al 2002; Kapur 
et al 2003). Treatment of facial lesions, and lesions on the 
scalp result in more pain. Also, the amount of pain seems to 
be related to the size of the treated area and type of lesion, 
since patients with AKs have been reported to experience 
more pain than patients with BCCs (Grapengiesser et al 
2002). There are reports that lower pain scores are obtained 
with MAL-PDT in comparison with ALA-PDT performed 
on tape-stripped normal skin (Wiegell et al 2003) and AKs 
(Kasche et al 2006). But even still, 4 out of the 28 AK 
patients included in the study by Kasche et al (2006) were 
not able to complete the treatment due to unbearable pain. 
Pain management most commonly involves local anesthet-
ics, premedication, fan-cooling or spraying the treated area 
with water. However, the pain-relieving effects are diverg-
ing. Cold air analgesia has shown some effect (Pagliaro et al 
2004), while tetracaine gel (Holmes et al 2004), capsaicin 
cream (Sandberg et al 2006), and morphine-gel (Skiveren 
et al 2006) seem to have no effect. Currently, no standard 
protocol for pain relief during PDT exists and further studies 
on the matter are desired.
Chronic side effects
Chronic side effects of topical PDT are rare. Only three case 
reports on contact allergy exist. One case report concerns 
contact allergy to ALA and the other two on MAL (Wulf 
and Philipsen 2004; Harries et al 2007). Thus, topical PDT 
can be considered to be a safe treatment.
Conclusion
Topical PDT, both with ALA and MAL, seems to offer a 
good therapeutic alternative to standard therapies in treating 
superﬁ  cial NMSC, especially if widespread areas or ﬁ  eld 
cancerization are involved. Treatment results are generally 
very good and the cosmetic results are excellent. Large areas 
of AK can easily be treated by topical-PDT, especially in the 
head and neck area, such as the scalp of old men. However, 
pain in these locations can sometimes be cumbersome to deal 
with and new pain-relieving strategies are required.
For BCCs, topical-PDT has proven especially suited for 
the superﬁ  cial form, particularly for treatment of thin and 
multiple superﬁ  cial BCCs. Also in this case, both clinical and 
cosmetic outcomes are excellent. Nodular BCCs are normally 
excised if possible. Surgery can easily be performed on the 
cheek, the forehead and the lips, but for lesions located on the 
nose, eyelids and external ear, simple excision is complicated. 
For these locations topical-PDT has shown some potiential, 
although thorough pre-treatment before application of ALA 
or MAL is necessary, and there is a risk for recurrences. In 
these instances, also cryotherapy may be good alternative to 
surgery (Lindgren and Larko 1997).
The OTRs constitute a patient group which suffer from 
widespread NMSC, and ﬁ  eld cancerization constitute a major 
problem. For these patients, topical-PDT has shown several 
advantages. In addition, compliance is less of a problem 
using topical-PDT as the physician has total control over the 
treatment as opposed to topical treatments, eg, 5-FU, which 
should be used for a prolonged period (several weeks) and 
often lead to compliance problems.
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